The ATLANTIC (Administration of ticagrelor in the cath lab or in the ambulance for new ST-segment elevation myocardial infarction to open the coronary artery) study indicates that pre-hospital administration of ticagrelor (Brilique, AstraZeneca)—as has been seen with pre-hospital administration of prasugrel (Efient, Eli Lilly)—does not improve coronary reperfusion before percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). However, it may reduce the risk of stent thrombosis.
ResMed has announced results from a major analysis of the German Statutory Health Insurance database presented at a Rapid Fire session at the ESC Congress 2014 in Barcelona, Spain. Results showed that the three-year mortality of people with sleep apnoea – a prevalent co-morbidity in coronary heart disease and heart failure – was significantly lower in patients who were treated with positive airway pressure devices compared to a comparable cohort that received no positive airway pressure treatment. Mortality was reduced by 37.9% in patients with coronary heart disease (p=0.0002) and by 31.6% in patients with heart failure (p<0.0001).
A new European joint consensus document on the use of antithrombotic drugs, including the non-vitamin K antagonist oral anticoagulants (NOACs), in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary intervention has been published in the European Heart Journal.
Claret Medical has announced that it has entered into an agreement for up to US$18 million in a Series B financing. The Series B round was led by Santé Ventures, a prominent healthcare-focused venture capital firm with US$260 million in capital under management, with participation from Lightstone Ventures, a leading venture capital firm with US$172 million under management. Easton Capital also joined the round. James Eadie from Santé Ventures and Hank Plain from Lightstone Ventures will be joining the company´s Board of Directors.
Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration to market its precision planning application for transcatheter aortic-valve implantation (TAVI) treatments. Through 3D imaging, the Philips TAVI application provides interventionalists with pre-procedural, high-precision positioning to treat aortic stenosis ailments.
Direct Flow Medical has announced that it has received the CE mark for a 23mm sized valve as part of its Direct Flow Medical transcatheter aortic valve system, expanding the patient population that can be treated with its technology. The company also announced receipt of the CE mark for implantation of all of its valves without the use of contrast media, protecting patients from kidney injury during transcatheter aortic valve implantation (TAVI).
Fabienne Witassek (AMIS Plus Data Centre, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland) report in Swiss Medical Weekly that the supposed obesity paradox—in which being obese seems to confer a mortality benefit—observed in some studies of patients with ST-segment elevation myocardial infarction (STEMI) may be at least partly explained by confounders. In the study, obese class I patients were younger and had less renal disease.
Micro Interventional Devices has reported the first successful clinical case using its Permaseal Cardiac Access and Closure technology. This new technology simplifies minimally invasive aortic valve replacement procedures. The patient is the first to be enrolled in the Secure Transapical Access and Closure Study (STASIS) being conducted in Europe.
Medtronic has announced the first US implants in the CoreValve Evolut R Clinical Study, which will evaluate the safety and effectiveness of the new Medtronic CoreValve Evolut R system. This novel investigational self-expanding valve and 14F equivalent delivery system offer new capabilities that are designed to advance deliverability and valve performance while providing the option to recapture and reposition the CoreValve Evolut R valve during deployment, if needed, while performing transcatheter aortic valve implantation (TAVI).
New methods that enhance the quality of myocardial perfusion imaging were developed in a recent study completed at the University of Eastern Finland. In her PhD study, Tuija Kangasmaa, invented a method which makes it possible to reduce the imaging time by up to 50%, making the scan session easier for the patient. Furthermore, the study also created two additional methods which correct errors resulting from patient movement during the scan. The methods were validated and they have already been taken into use in hospitals all over the world.
EndoCross has received CE mark approval for the Enabler-C coronary catheter system. The Enabler-C features a unique controlled guidewire advancement technology currently available in the CE marked Enabler-P peripheral catheter systems. The CE mark of the Enabler-C coronary catheter system follows the successful first-in-man study of the Enabler-C that took place at the Institut Cardiovasculaire Paris-Sud.
Stentys has announced that its Self-Apposing stent has been implanted more than 10,000 times in patients worldwide. A company press release reports that this milestone further illustrates the popularity of Stentys’ technology among cardiologists in Europe and a growing number of regions globally. It adds that the stent solves the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents.
Physicians at the Heart Hospital of Austin became the first in Texas to implant the new Portico re-sheathable transcatheter aortic valve implantation (TAVI) device as part of the PORTICO trial, which is a nationwide clinical study to examine the effectiveness of the new heart valve. The TAVI procedure was first performed in Central Texas at the Heart Hospital of Austin in February 2012.
BIOTRONIK has enrolled the final patient in the BIOHELIX-I clinical trial. The BIOHELIX–I trial is designed to evaluate the safety and efficacy of the PRO-Kinetic Energy coronary bare metal stent and supports US Food and Drug Administration approval for the treatment of coronary arteries. BIOTRONIK previously received CE mark approval for PRO-Kinetic Energy in 2009.
Boston Scientific Corporation has received CE mark approval and begun the European commercial launch of its new 25mm Lotus transcatheter aortic valve implantation (TAVI) system, complementing the currently available 23mm and 27mm valve sizes.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos